2021
DOI: 10.1021/acs.cgd.1c00150
|View full text |Cite
|
Sign up to set email alerts
|

Novel Formulations of the Antiviral Drug Favipiravir: Improving Permeability and Tabletability

Abstract: Recently, favipiravir, as a broad-spectrum antiviral drug, has gain more attention because it might be a candidate to remedy the coronavirus disease 2019 (COVID-19). To improve its poor permeability and tabletability, four multicomponent crystals of favipiravir (FPV) were prepared by a slow evaporation or liquidassisted grinding method, including three cocrystals (FPVtheophylline, 1:1; FPV-saccharin, 1:1; FPV-5-fluorouracil, 1:1) and one salt (FPV-piperazine, 2:1). All of the crystal structures were solved by … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

2
11
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 20 publications
(13 citation statements)
references
References 62 publications
2
11
0
Order By: Relevance
“…However, a similar search for FAV as of 2021, the CSD reports no adduct forms as this molecule as a coformer. However, very recent report of a similar THP-FAV cocrystal has emerged [73] but we can offer a more detailed view of crystal packing consistent with the robustness of this phase under the range of formulation conditions described.…”
Section: Single Crystal X-ray Diffractionsupporting
confidence: 60%
“…However, a similar search for FAV as of 2021, the CSD reports no adduct forms as this molecule as a coformer. However, very recent report of a similar THP-FAV cocrystal has emerged [73] but we can offer a more detailed view of crystal packing consistent with the robustness of this phase under the range of formulation conditions described.…”
Section: Single Crystal X-ray Diffractionsupporting
confidence: 60%
“…Compared with the commercial form-I, the above results demonstrate that the permeability of novel ETP form-II is superior to that of the marketed form-I. Permeability of the commercial form-I is lower than that of the other polymorphs, and this observation prompts further studies to enhance not just solubility/dissolution but also drug permeability/flux pass in pharmaceutical crystal forms. …”
Section: Resultsmentioning
confidence: 89%
“…Thus, both have low water solubility. In contrast, the ionic size, solubility and lipophilicity of Favipiravir (Log P = -0.49) [50] and Molnupiravir (Log P = -0.8) [51] compared to RDS ions is primarily responsible for the strong selectivity against these compounds as they are more water soluble and less lipophilic in addition to their low molecular weights. Also, inorganic cations as sodium and potassium did not interfere due to the variations in their ionic size, mobility, and permeability when compared to the RDS ions.…”
Section: Resultsmentioning
confidence: 99%